At present, the dramatic rise in antimicrobial resistance (AMR) among important human
bacterial pathogens is reaching a state of global crisis threatening a return to the pre …

The Gram-positive anaerobic bacterium Clostridium difficile produces toxins A and B, which
can cause a spectrum of diseases from pseudomembranous colitis to C. difficile-associated …

Background Clostridium difficile infection can result in asymptomatic carriage, mild diarrhea,
or fulminant pseudomembranous colitis. We studied whether antibody responses to C …

Background We have reported that symptom-free carriers of Clostridium difficile have a
systemic anamnestic immune response to toxin A. The aim of this study was to determine …

A total of 271 patients were prospectively followed up to determine whether patients whose
hospital stay is complicated by diarrhea due to Clostridium difficile experience differences in …

Saccharomyces boulardii is a nonpathogenic yeast that protects against antibiotic-
associated diarrhea and recurrent Clostridium difficile colitis. The administration of C. difficile …

Objective: To determine the diagnostic accuracy of an index of underlying disease severity
(Horn's index) in identifying patients with a high probability of having nosocomial Clostridium …

Background & aims: Recurrent C difficile-associated diarrhea (CDAD) is associated with a
lack of protective immunity to C difficile toxins. A parenteral C difficile vaccine containing …

Clostridium difficile infection is an increasing burden to the health care system, totaling more
than $1 billion/year in the United States. Treatment of patients with C difficile infection with …

There is a strong association between serum antibody responses to toxin A and protection
against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very …